TNSN07087A1 - Stable liquid formulations of plasmid dna - Google Patents

Stable liquid formulations of plasmid dna

Info

Publication number
TNSN07087A1
TNSN07087A1 TNP2007000087A TNSN07087A TNSN07087A1 TN SN07087 A1 TNSN07087 A1 TN SN07087A1 TN P2007000087 A TNP2007000087 A TN P2007000087A TN SN07087 A TNSN07087 A TN SN07087A TN SN07087 A1 TNSN07087 A1 TN SN07087A1
Authority
TN
Tunisia
Prior art keywords
plasmid dna
plasmid
liquid formulations
dna
stable
Prior art date
Application number
TNP2007000087A
Inventor
Francis Blanche
Michel Couder
Nicolas Maestrali
Thierry Guillemin
David Gaillac
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of TNSN07087A1 publication Critical patent/TNSN07087A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention relates to plasmid DNA liquid formulations that are stable and stays un-degraded at +4°C to room temperature for long periods of time, and are thus useful for storage of plasmid DNA that are used research, plasmid-based therapy, such as DNA vaccine and gene therapy. The present invention also relates to a method of preserving plasmid DNA in a stable form over time at +4°C to room temperature. The present invention also relates to stable plasmid DNA liquid compositions for use in a method of treatment of the human or animal body by plasmid-based therapy, such as DNA vaccination or gene therapy.
TNP2007000087A 2005-09-19 2007-03-08 Stable liquid formulations of plasmid dna TNSN07087A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (1)

Publication Number Publication Date
TNSN07087A1 true TNSN07087A1 (en) 2008-06-02

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000087A TNSN07087A1 (en) 2005-09-19 2007-03-08 Stable liquid formulations of plasmid dna

Country Status (14)

Country Link
EP (1) EP1791945A1 (en)
JP (1) JP2008512997A (en)
KR (1) KR20070058621A (en)
CN (1) CN101040041A (en)
AU (1) AU2005284244A1 (en)
BR (1) BRPI0515553A (en)
CA (1) CA2579340A1 (en)
EA (1) EA011554B1 (en)
IL (1) IL181753A0 (en)
MX (1) MX2007003214A (en)
NO (1) NO20071946L (en)
NZ (1) NZ553914A (en)
TN (1) TNSN07087A1 (en)
WO (1) WO2006029908A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (en) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Method for preparing pharmaceutical composition for inducing angiogenesis in tissues, pharmaceutical composition prepared by this method, and method of treating individual's tissue and/or organ ischemia
CN104032005B (en) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 A kind of preservatives of PCR order-checking intermediate product and store method
US20180036409A1 (en) * 2014-12-29 2018-02-08 Bonac Corporation Composition containing nucleic acid molecule stably
RU2612497C2 (en) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Optimized nucleotide sequence and pharmaceutical compositions based thereon with sustained vegf transgene expression
RU2628087C1 (en) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Composition with antimicrobial action for storage of dna or dna-containing preparations (versions) and its application
CN106554956A (en) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 A kind of method that industrialization prepares BCG CpG DNA
WO2019023937A1 (en) * 2017-08-01 2019-02-07 深圳华大智造科技有限公司 Highly efficient endonuclease buffer system
US11248257B2 (en) 2017-08-25 2022-02-15 Zoetis Services Llc Method of immobilizing a nucleic acid probe to a solid support
EP3714252B1 (en) 2017-11-22 2023-05-31 Beckman Coulter, Inc. Diluent preparation module und method for supplying such diluent
EP3844301A1 (en) * 2018-08-30 2021-07-07 GlaxoSmithKline Intellectual Property Development Ltd Methods of detecting nucleic acid
CN111718961B (en) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 Method for transforming bacteria by using plasmid
CN115404232A (en) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 Method for extracting plasmid DNA from bacteria
WO2023182614A1 (en) * 2022-03-24 2023-09-28 주식회사 헬릭스미스 Liquid formulation pharmaceutical composition comprising plasmid dna

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (en) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc BACTERIA LYSIS PROCESS AND DEVICE
JP2003516741A (en) * 1999-12-17 2003-05-20 メルク エンド カムパニー インコーポレーテッド Polynucleotide vaccines expressing codon-optimized HIV-1Nef and modified HIV-1Nef

Also Published As

Publication number Publication date
CN101040041A (en) 2007-09-19
WO2006029908A1 (en) 2006-03-23
MX2007003214A (en) 2007-10-11
KR20070058621A (en) 2007-06-08
BRPI0515553A (en) 2008-07-29
EA200700656A1 (en) 2007-10-26
JP2008512997A (en) 2008-05-01
NO20071946L (en) 2007-05-29
AU2005284244A1 (en) 2006-03-23
EA011554B1 (en) 2009-04-28
NZ553914A (en) 2009-11-27
CA2579340A1 (en) 2006-03-23
EP1791945A1 (en) 2007-06-06
IL181753A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
TNSN07087A1 (en) Stable liquid formulations of plasmid dna
PH12015500549A1 (en) Hppd variants and methods of use
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
MX2007007602A (en) Glp-1 agonists, compositions, methods and uses.
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2007035213A3 (en) Transgenic ungulates expressing ctla4-ig and uses thereof
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
SG149829A1 (en) Pyrazolopyridines and analogs thereof
WO2004067753A3 (en) Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
UA101301C2 (en) Isolated il-23pl9 antibody and use thereof
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
UA111464C2 (en) The composition containing c1-c7 and glycerin, and its use as antibacterial and inhibiting agent
WO2007022030A3 (en) Methods and compositions for the efficient delivery of therapeutic agents to cells and animals
IN2015DN02729A (en)
WO2011026614A3 (en) Compositions and methods for disinfecting materials
EP2574170A4 (en) Immunostimulatory and vaccine compositions
GB201001602D0 (en) Oligopeptidic compounds and uses therof
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
BR112012016128A2 (en) therapeutic agent (y-39983) for corneal endothelial dysfunction
WO2019098759A3 (en) Transformed human cell and use thereof
TW200724679A (en) Treatment of disease using an improved regulated expression system
HUP0203469A2 (en) Means and methods for enhhancing the content of sulfur compounds in plants
MX2013013098A (en) Methods and compositions for promoting lean body mass growth.